IO360° Summit

Patrick Hwu, MD, President and CEO, Moffitt Cancer Center

9:25AM - 9:50AM

Keynote: Historical Perspective of Tumor Vaccines with an Emphasis on Why the Newest RNA Vaccines May Work Where Others Could Not

Margaret Callahan, MD, PhD, Medical Oncologist and Immunotherapeutics Program Research Director, University of Connecticut

Showing Events in 1 Track from 09:50am to 10:30am

Morning IO360° Breakfast, Networking, Exhibits & One-on-One Meetings

9:50AM - 10:30AM

Morning IO360° Breakfast, Networking, Exhibits & One-on-One Meetings

Showing Events in 2 Tracks from 10:30am to 12:25pm

Track A: IO and Cell Therapy Clinical Developments A (Salon ABC)

Track Chair:

Vanessa Lucey, PhD, MBA, Director, WW Oncology Commercialization, Early Assets, BMS

Targeting Clonal Neoantigens with Precision Cell Therapies

Sergio Quezada, PhD, Professor of Cancer Immunology and Immunotherapy / CSO, University College London Cancer Institute / Achilles Therapeutics

Advancing the Clinical Development of a CRISPR Genome-edited Allogeneic CAR-T Cell Therapy

Tonia Nesheiwat, PharmaD, VP, Medical Affairs, Caribou Biosciences

Conditionally Active Antibodies in Immuno-Oncology: Selectively Targeting VISTA in the Acidic Tumor Microenvironment

Edward van der Horst, PhD, CSO, Sensei Bio

Circulating Tumor DNA Profiling for Accelerated Drug Development

Dejan Knezevic, PhD, Senior Business Development Director, Guardant Health

Development of T-Cell Engagers for Solid Tumors Clinical Updates and Lessons Learned

Judd Englert, MD, PhD, Executive Medical Director, Oncology, Amgen

Therapeutic Targeting of Regulatory T cells in Cancer by Blocking Migration to the Tumor Microenvironment: A Novel Approach

Dirk Brockstedt, PhD, CSO, RAPT Therapeutics, Inc.

Track B: IO and Cell Therapy Clinical Developments B (Salon DE)

Track Chair:

Raluca Verona, PhD, Head, Oncology Precision Medicine Group, AbbVie

Strategies to Overcome Limitations of Cell Therapies in Cancer Treatment

Erin Karski, MD, Executive Medical Director, Cell Therapy, Early Oncology R&D, AstraZeneca

Next-gen TCR-based Cell Therapies and Bispecifics for Solid Cancers

Harpreet Singh, PhD, CEO, Immatics

Combination Chemotherapy, Motixafortide (CXCR4 Inhibitor), and Cemiplimab (Anti-PD1) in First Line Metastatic Pancreatic Cancer

Gulam Manji, MD, PhD, Associate Professor of Medicine, Columbia University Irving Medical Center

Expanding a CAR gamma delta T cell Pipeline in Autoimmune Diseases and Oncology

Blake Aftab, PhD, CSO, Adicet Bio

Emerging Clinical Portfolio of Immuno-Oncology and Targeted Therapies

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Simultaneously Improving IL-2 Potency and Removing Toxicity with Targeted DK210 (EGFR)

John Mumm, PhD, President & CEO, DEKA Biosciences

Showing Events in 1 Track from 12:25pm to 01:25pm

Lunch on Own & One-on-One Meetings

12:25PM - 1:25PM

Lunch on Own & One-on-One Meetings

Showing Events in 1 Track from 01:25pm to 02:50pm

IO Clinical Developments Continued (Salon DE)

1:25PM - 1:45PM

Systematic Evaluation of TIGIT

Tanya Keenan, MD, MPH, Executive Director, Oncology Clinical Development, Merck

1:45PM - 2:05PM

Update on IO Biotech’s Immune Modulating Cancer Vaccine

Mai-Britt Zocca, PhD, Founder and CEO, IO Biotech

2:05PM - 2:25PM

Tumor Targeted IO - Right Target, Right Tumor, Right Modality, a Focus on TGFb

Rachel Salazar, DHSc, SVP, R&D Strategy & Operations, Bicara Therapeutics

2:25PM - 2:45PM

Dostarlimab Data Update for MSI-High Rectal Cancer

Benoit Rousseau, MD, PhD, Assistant Attending Physician / Assistant Lab Member, Memorial Sloan Kettering Cancer Center

2:45PM - 2:50PM

End of Day Three

Showing Events in 1 Track from 08:20am to 09:00am

Day 3 Morning General Session

8:20AM - 8:50AM

Registration

8:50AM - 9:00AM

IO360° Day Three Welcome

Chair:

Alex Snyder, MD, EVP, Research and Development, Generate Biomedicines

Showing Events in 1 Track from 09:00am to 09:50am

Morning Keynotes & IO Clinical Developments

9:00AM - 9:25AM

CEO Keynote: The Future of TIL Therapy

Patrick Hwu, MD, President and CEO, Moffitt Cancer Center

9:25AM - 9:50AM

Keynote: Historical Perspective of Tumor Vaccines with an Emphasis on Why the Newest RNA Vaccines May Work Where Others Could Not

Margaret Callahan, MD, PhD, Medical Oncologist and Immunotherapeutics Program Research Director, University of Connecticut

Showing Events in 1 Track from 09:50am to 10:30am

Morning IO360° Breakfast, Networking, Exhibits & One-on-One Meetings

9:50AM - 10:30AM

Morning IO360° Breakfast, Networking, Exhibits & One-on-One Meetings

Showing Events in 2 Tracks from 10:30am to 12:25pm

Track A: IO and Cell Therapy Clinical Developments A (Salon ABC)

Track Chair:

Vanessa Lucey, PhD, MBA, Director, WW Oncology Commercialization, Early Assets, BMS

Targeting Clonal Neoantigens with Precision Cell Therapies

Sergio Quezada, PhD, Professor of Cancer Immunology and Immunotherapy / CSO, University College London Cancer Institute / Achilles Therapeutics

Advancing the Clinical Development of a CRISPR Genome-edited Allogeneic CAR-T Cell Therapy

Tonia Nesheiwat, PharmaD, VP, Medical Affairs, Caribou Biosciences

Conditionally Active Antibodies in Immuno-Oncology: Selectively Targeting VISTA in the Acidic Tumor Microenvironment

Edward van der Horst, PhD, CSO, Sensei Bio

Circulating Tumor DNA Profiling for Accelerated Drug Development

Dejan Knezevic, PhD, Senior Business Development Director, Guardant Health

Development of T-Cell Engagers for Solid Tumors Clinical Updates and Lessons Learned

Judd Englert, MD, PhD, Executive Medical Director, Oncology, Amgen

Therapeutic Targeting of Regulatory T cells in Cancer by Blocking Migration to the Tumor Microenvironment: A Novel Approach

Dirk Brockstedt, PhD, CSO, RAPT Therapeutics, Inc.

Track B: IO and Cell Therapy Clinical Developments B (Salon DE)

Track Chair:

Raluca Verona, PhD, Head, Oncology Precision Medicine Group, AbbVie

Strategies to Overcome Limitations of Cell Therapies in Cancer Treatment

Erin Karski, MD, Executive Medical Director, Cell Therapy, Early Oncology R&D, AstraZeneca

Next-gen TCR-based Cell Therapies and Bispecifics for Solid Cancers

Harpreet Singh, PhD, CEO, Immatics

Combination Chemotherapy, Motixafortide (CXCR4 Inhibitor), and Cemiplimab (Anti-PD1) in First Line Metastatic Pancreatic Cancer

Gulam Manji, MD, PhD, Associate Professor of Medicine, Columbia University Irving Medical Center

Expanding a CAR gamma delta T cell Pipeline in Autoimmune Diseases and Oncology

Blake Aftab, PhD, CSO, Adicet Bio

Emerging Clinical Portfolio of Immuno-Oncology and Targeted Therapies

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Simultaneously Improving IL-2 Potency and Removing Toxicity with Targeted DK210 (EGFR)

John Mumm, PhD, President & CEO, DEKA Biosciences

Showing Events in 1 Track from 12:25pm to 01:25pm

Lunch on Own & One-on-One Meetings

12:25PM - 1:25PM

Lunch on Own & One-on-One Meetings

Showing Events in 1 Track from 01:25pm to 02:50pm

IO Clinical Developments Continued (Salon DE)

1:25PM - 1:45PM

Systematic Evaluation of TIGIT

Tanya Keenan, MD, MPH, Executive Director, Oncology Clinical Development, Merck

1:45PM - 2:05PM

Update on IO Biotech’s Immune Modulating Cancer Vaccine

Mai-Britt Zocca, PhD, Founder and CEO, IO Biotech

2:05PM - 2:25PM

Tumor Targeted IO - Right Target, Right Tumor, Right Modality, a Focus on TGFb

Rachel Salazar, DHSc, SVP, R&D Strategy & Operations, Bicara Therapeutics

2:25PM - 2:45PM

Dostarlimab Data Update for MSI-High Rectal Cancer